Targovax announces formation of new Scientific Advisory Board
Oslo, Norway, 28 October 2020 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces the formation of a new Scientific Advisory Board (SAB). The SAB consists of a group of world-renowned experts in immuno-oncology research and drug development carefully selected to act as advisors to guide the Targovax R&D strategy.Victor Levitsky, Chief Scientific Officer of Targovax said: We are very pleased to have attracted such high caliber individuals with deep expertise in immuno-oncology to serve on the